What are you searching for?

Sign in
News Releases

METABOLIC SYNDROME STUDY ON SABINSA’S CURCUMIN C3 COMPLEX® HONORED

WITH UNIVERSITY RESEARCH OF THE YEAR AWARD

Company Logo

Released By Sabinsa Corporation

Geneva Switzerland (May 18, 2016) – A study that found benefits in metabolic syndrome patients given Sabinsa Corporation’s Curcumin C3 Complex was chosen by a panel of experts for the NutraIngredients University Research of the Year Award, announced last week in Geneva, Switzerland. This award, given to research that “takes the nutrition sector to a new level of understanding, with clear potential for the development of market changing products,” honored the study conducted at Mashhad University of Medical Sciences on C3 Complex and metabolic syndrome.

This study investigates the safety and efficacy of Curcumin C3 Complex in management of serum lipid concentrations in metabolic syndrome patients. The study results showed that Curcumin C3 Complex plus BioPerine® combination was well tolerated and also improved the serum lipid health in metabolic syndrome patients. (Panahi Y, Khalili N, Hosseini MS, Abbasinazari M, Sahebkar A. Lipid-­‐modifying effects of adjunctive therapy with curcumioids-­‐piperine combination in patients with metabolic syndrome: Results of a randomized controlled trial. Complementary Therapies in Medicine ; 2014; 22(5): 851-­‐57).

Eight-­‐week supplementation with Curcumin C3 Complex and BioPerine was associated with a reduction of serum triglycerides, total cholesterol, serum low density lipoprotein-­‐cholesterol, non-­‐high density lipoprotein cholesterol, lipoprotein (a) and increase in the high density lipoprotein cholesterol (HDL) as compared to placebo.

“Curcumin C3 Complex is the most studied Curcumin ingredient on the market, primarily for inflammation, but this study is particularly significant in that it investigates another condition that has serious health implications in a large percentage of the population,” said Sabinsa founder Dr. Muhammed Majeed. “We thank NutraIngredients and their panel of experts for acknowledging the significance of this research and we thank the researchers for carrying out this important new study.”

About Sabinsa Corporation:
Sabinsa’s mission is to provide alternative and complementary natural products for human nutrition and well-­‐being. Over the past 27 years, Sabinsa has brought to market more than 100 standardized botanical extracts, and privately funded clinical studies in conjunction with prestigious institutions in support of these products. With more than 100 full-­‐time scientists conducting ongoing research in India and the United States, Sabinsa and parent company Sami Labs Ltd. continue to develop, patent and manufacture phytonutrients for the world market, with ingredients that are both Halal and Kosher. For more information, visit www.sabinsa.com.

Request more information from Sabinsa Corporation

Request more information from Sabinsa Corporation

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters

Related Library